AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10826401
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) (12.5 to 25 mg)
Trial: 6397541
Drug: Behaviourally-oriented weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviourally-oriented weight loss ('diet') programme administered by professional dietitians
Trial: 3537101
Drug: Sodium ipodate
RxNorm normalized name: ipodate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ipodate (1 g daily for 10 days)
Trial: 3537101
Drug: Saturated solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saturated solution of potassium iodide (SSKI, 12 drops daily for 10 days)
Trial: 25031274
Drug: Erlotinib (100mg)
RxNorm normalized name: erlotinib 100 MG
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib (100mg) plus WBRT (20 Gy in 5 fractions) followed by maintenance erlotinib (150 mg)
Trial: 17973974
Drug: Dextofisopam 200
RxNorm normalized name: tofisopam
DrugBank: Tofisopam (DB08811)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Dextofisopam 200 mg b.d. for 12 weeks
Trial: 12456597
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin administration
Trial: 12832248
Drug: Individual plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual plus group drug counseling
Trial: 12832248
Drug: Other psychosocial
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other psychosocial treatments (not specified)
Trial: 2060439
Drug: Metformin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1 g three times daily)
Trial: 6650766
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg of furosemide as a bolus injection at time 0 and again 6 hours later
Trial: 6650766
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg per hour of furosemide as a constant infusion for 12 hours
Trial: 26762988
Drug: BMS-986001 100
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986001 100 mg once a day
Trial: 26762988
Drug: BMS-986001 200
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986001 200 mg once a day
Trial: 26762988
Drug: BMS-986001 400
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986001 400 mg once a day
Trial: 23942319
Drug: Liraglutide 1.2-3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.2-3.0 mg
Trial: 23942319
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg × 3 per day
Trial: 22978588
Drug: Herbal extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal extract (HEX) at 50 mg/kg diet
Trial: 22978588
Drug: Monensin (MON)
RxNorm normalized name: Monensin
DrugBank: Monensin (DB11430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monensin (MON) at 100 mg/kg diet
Trial: 17006376
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone protein plus soy lecithin (25 g/day + 20 g/day)
Trial: 17006376
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone protein (25 g/day)
Trial: 17006376
Drug: Soy lecithin
RxNorm normalized name: Soy Lecithin
DrugBank: Lecithin, soybean (DB14161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy lecithin (20 g/day)
Trial: 9139527
Drug: Pefloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (800 mg as single dose)
Trial: 9139527
Drug: Ciprofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (250 mg/8 h/72 h)
Trial: 1871323
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release formulation (MPH-IR) with a regular dose of 10mg (n=5) and 5mg (n=1) of methylphenidate (MPH) in the first pilot study.
Trial: 1871323
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release formulation (MPH-SR) with a regular dose of 20mg of methylphenidate (MPH) in the second pilot study.
Trial: 6384510
Drug: Control (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (group therapy only)
Trial: 22859321
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate treatment protocol for acute severe asthma exacerbation
Trial: 22859321
Drug: Standard protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protocol for the initial treatment of acute asthma exacerbation (Control group)
Trial: 20301114
Drug: Chemotherapy (cisplatin/fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin/fluorouracil plus either docetaxel or epirubicin)
Trial: 16011771
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (15 teeth) prepared with Hero Shapers and irrigated with 5 mL of EDTA (10%) and 5 mL of 5% NaOCl at 50 degrees C, no electrical pulse treatment
Trial: 2358942
Drug: Naproxen sodium,
RxNorm normalized name: Naproxen Sodium, sodium compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen sodium, 550 mg administered 30 minutes postoperatively
Trial: 2358942
Drug: Naproxen sodium,
RxNorm normalized name: Naproxen Sodium, sodium compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen sodium, 550 mg administered 30 minutes preoperatively
Trial: 31009339
Drug: Tenecteplase 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase 0.4 mg/kg
Trial: 27521828
Drug: Brief smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief smoking cessation intervention (protocolized counseling, medications, referrals to a quitline)
Trial: 24620920
Drug: ADV in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV in combination with HB‐110
Trial: 21757932
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg) injected through the tonsillar capsule
Trial: 19337628
Drug: Oral Buscopan
RxNorm normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Buscopan (20 mg three times a day, n=37)
Trial: 19337628
Drug: Buscopan Suppository
RxNorm normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buscopan Suppository (30 mg once daily, n=21)
Trial: 19337628
Drug: Oral Drotaverine
RxNorm normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Drotaverine (80 mg three times a day, n=30)
Trial: 19337628
Drug: Calcium Gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Gluconate Tablets (one three times a day, n=16)
Trial: 19337628
Drug: Calendula Suppository
RxNorm normalized name: CALENDULA
DrugBank: Calendula officinalis whole (DB14315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calendula Suppository (once daily, n=14)
Trial: 19337628
Drug: Oral Buscopan
RxNorm normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Buscopan
Trial: 19337628
Drug: Rectal Buscopan
RxNorm normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal Buscopan
Trial: 19337628
Drug: Oral Drotaverine
RxNorm normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Drotaverine
Trial: 11356239
Drug: Monotherapy (either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (either IPT or NT alone)
Trial: 11356239
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment (combined NT and IPT)
Trial: 7939146
Drug: Oxymetazoline spray
RxNorm normalized name: oxymetazoline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline spray
Trial: 7939146
Drug: Oxymetazoline solution
RxNorm normalized name: oxymetazoline Ophthalmic Solution
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetazoline solution
Trial: 3377149
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion of 0.075% bupivacaine at a rate of 12‐18 ml/hour
Trial: 4890523
Drug: Methyldopa (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (high doses)
Trial: 28659138
Drug: Comprehensive Geriatric
RxNorm normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Geriatric Assessment (CGA) and intervention before and during chemotherapy
Trial: 28659138
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy regimens and standard of care
Trial: 21627518
Drug: Nalbuphine HCl
RxNorm normalized name: nalbuphine HCl
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalbuphine HCl (12.5 mg/kg) IV administration
Trial: 21627518
Drug: Nalbuphine HCl
RxNorm normalized name: nalbuphine HCl
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalbuphine HCl (12.5 mg/kg) IM administration
Trial: 19531212
Drug: Letrozole (aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (aromatase inhibitor)
Trial: 15531673
Drug: l‐rhamnose (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐rhamnose (25 g for 28 days)
Trial: 15531673
Drug: lactulose (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactulose (25 g for 28 days)
Trial: 7877519
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal oestradiol for 3 months
Trial: 7877519
Drug: Cyclical transdermal
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical transdermal oestradiol with medroxyprogesterone acetate for 3 months
Trial: 14552308
Drug: Auranofin (AF)
RxNorm normalized name: Auranofin
DrugBank: Auranofin (DB00995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auranofin (AF) therapy
Trial: 23460707
Drug: Single early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single early intravesical instillation of pirarubicin (THP) 30 mg in 30 mL of saline
Trial: 10902988
Drug: E supplement
RxNorm normalized name: Iodine supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E supplement (1171 kJ + 12 mg iron)
Trial: 10902988
Drug: M supplement
RxNorm normalized name: Sodium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M supplement (209 kJ + 12 mg iron)
Trial: 10902988
Drug: S supplement
RxNorm normalized name: Phosphorus supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S supplement (104 kJ)
Trial: 29187694
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day pitavastatin
Trial: 29212965
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/day pitavastatin
Trial: 25330142
Drug: 3 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg/day enteric-coated aspirin tablets for 6 months
Trial: 25330142
Drug: 5 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg/day enteric-coated aspirin tablets for 6 months
Trial: 21904634
Drug: 0.1% NVC-422
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% NVC-422 topical gel
Trial: 21904634
Drug: 0.5% NVC-422
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% NVC-422 topical gel
Trial: 21904634
Drug: 1.5% NVC-422
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% NVC-422 topical gel
Trial: 21904634
Drug: NVC-422 topical
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVC-422 topical gel (all doses)
Trial: 1482300
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) nebulized solution
Trial: 30222804
Drug: CLS‐TA (triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLS‐TA (triamcinolone acetonide injectable suspension)
Trial: 27287210
Drug: Doxycycline (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (oral, 4 weeks)
Trial: 27287210
Drug: Placebo (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral, 4 weeks)
Trial: 27287210
Drug: Alclometasone (topical)
RxNorm normalized name: alclometasone Topical Cream
DrugBank: Alclometasone (DB00240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alclometasone (topical) plus VSL#3 (oral)
Trial: 27287210
Drug: VSL#3 (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VSL#3 (oral)
Trial: 25241229
Drug: Chemoradiotherapy (CHRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (CHRT) with fluorouracil (5 FU) infusion and cisplatin, associated with radiotherapy (50 Gy)
Trial: 22857987
Drug: Mental practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental practice in addition to occupational therapy
Trial: 12551706
Drug: Levodopa/benserazide (200/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/benserazide (200/50 mg) with a high-fat breakfast
Trial: 12551706
Drug: Levodopa/benserazide (200/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/benserazide (200/50 mg) in fasting conditions
Trial: 12551706
Drug: Levodopa/benserazide (200/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/benserazide (200/50 mg) with food
Trial: 10513411
Drug: Telviran (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telviran (800 mg acyclovir)
Trial: 10513411
Drug: Zovirax (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zovirax (800 mg acyclovir)
Trial: 2028627
Drug: SR PPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR PPA 75 mg/d
Trial: 6106501
Drug: Combined sedative
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sedative and anxiolytic preparations (specific combinations not detailed)
Trial: 6106501
Drug: Amylobarbitone sodium
RxNorm normalized name: Amylobarbitone sodium
DrugBank: Amobarbital (DB01351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amylobarbitone sodium (established hypnotic)
Trial: 6106501
Drug: Clobazam/dichloralphenazone (anxiolytic/sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam/dichloralphenazone (anxiolytic/sedative combination)
Trial: 28675660
Drug: First-line intercalated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line intercalated chemotherapy + erlotinib, maintenance erlotinib in patients with EGFR mutations
Trial: 28675660
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy + bevacizumab, maintenance bevacizumab in EGFR wild-type patients
Trial: 28675660
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + conatumumab, maintenance conatumumab in patients with squamous histology
Trial: 28675660
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + cetuximab, maintenance cetuximab or chemotherapy + necitumumab, maintenance necitumumab in EGFR FISH-positive patients with squamous histology
Trial: 28675660
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy + bevacizumab, maintenance bevacizumab or first-line sequential chemotherapy + gefitinib, maintenance gefitinib in patients clinically enriched for EGFR mutations with nonsquamous histology
Trial: 26393645
Drug: Low-carbohydrate diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate diet (<40 g/day), n = 75
Trial: 15385382
Drug: Isobaric 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric 0.5% bupivacaine, 18 mg plus saline (Group 1, control)
Trial: 9699431
Drug: Patient-controlled TENS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled TENS at the injection site
Trial: 9699431
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia (2 min application of 20% benzocaine)
Trial: 2513630
Drug: Nonabsorbable agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonabsorbable agents
Trial: 1269214
Drug: Experimental soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental soft gelatin formulations of digoxin in solution
Trial: 1269214
Drug: Capsules of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of digoxin
Trial: 1269214
Drug: Tablets of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of digoxin
Trial: 12615868
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g every 8 h (C3 x 2)
Trial: 12615868
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g as a loading dose, followed by ceftazidime 2 g over 7 h every 12 h (C2 x 2)
Trial: 10669372
Drug: Meningococcal AC
RxNorm normalized name: meningococcal AC polysaccharide (non-US)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal AC polysaccharide (MACP) vaccine
Trial: 26414626
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxytocin and motherwort injection
Trial: 8889352
Drug: Atenolol, Amlodipine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol, Amlodipine, or Enalapril (three antihypertensive drug regimens)
Trial: 8889352
Drug: Attendance at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attendance at scheduled monthly follow-up visits
Trial: 8889352
Drug: Overall attendance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall attendance and medication adherence
Trial: 1984386
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms of hepatitis B vaccine
Trial: 6684932
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of 20 mg diltiazem in 20 min
Trial: 6684932
Drug: peroral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peroral solution of 120 mg diltiazem
Trial: 6684932
Drug: two 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 60 mg tablets of diltiazem (Dilzem)
Trial: 29681015
Drug: Cryotherapy (cooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy (cooled glove/sock worn for 15 min before, during, and after paclitaxel infusion)
Trial: 25516315
Drug: Probiotics three
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics three times daily for 8 days
Trial: 20678136
Drug: Vertical augmentation
RxNorm normalized name: Verticalm
DrugBank: Meclizine (DB00737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vertical augmentation with anorganic bovine bone blocks and delayed 5-month placement of ≥10 mm implants
Trial: 20678136
Drug: 7-mm-long implants
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-mm-long implants
Trial: 20678136
Drug: Vertical augmentation
RxNorm normalized name: Verticalm
DrugBank: Meclizine (DB00737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vertical augmentation with anorganic bovine bone blocks
Trial: 19887674
Drug: Etoricoxib (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (selective COX-2 inhibitor)
Trial: 16371185
Drug: Calcium carbonate/cholecalciferol
RxNorm normalized name: ipriflavone/calcium carbonate/cholecalciferol (vit D3) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium carbonate/cholecalciferol therapy (calcium carbonate: 1500 mg per day; cholecalciferol 400 UI per day)
Trial: 16371185
Drug: Calcium lactogluconate/calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium lactogluconate/calcium carbonate (mg 300 per day)
Trial: 2106714
Drug: Cyclic estradiol-desogestrel
RxNorm normalized name: desogestrel / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic estradiol-desogestrel therapy for 6 months
Trial: 26910781
Drug: Clindamycin-Gentamicin solution
RxNorm normalized name: gentamicin Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin-Gentamicin solution (Group 2)
Trial: 19047285
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg on days 1 and 2 with chemotherapy on day 3 (150 PRE)
Trial: 19047285
Drug: Erlotinib 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 1,500 mg on days 1 and 2 with chemotherapy on day 3 (1,500 PRE)
Trial: 19047285
Drug: Chemotherapy on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy on day 1 with erlotinib 1,500 mg on days 2 and 3 (1,500 POST)
Trial: 17606173
Drug: Studies with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Studies with concurrent economic evaluation